An analysis of radiation necrosis of the central nervous system treated with bevacizumab
- 1.5k Downloads
Radiation necrosis is a devastating complication following radiation to the central nervous system. The purpose of this study was to perform a comprehensive analysis of cases in the literature using bevacizumab, a monoclonal antibody against vascular endothelial growth factor, as treatment for radiation necrosis. A MEDLINE/PubMed search of articles about the use of bevacizumab for radionecrosis treatment yielded 16 studies published between 2007 and 2012. Data was summarized according to patient characteristics, treatment received and outcomes measured. A total of 71 unique cases were identified that met the inclusion criteria. The median age at the time of treatment with bevacizumab was 47 years. The most common tumors treated were glioblastoma (31 %), anaplastic glioma (14 %), and metastatic brain tumors (15 %). The median time from ending radiotherapy to starting treatment with bevacizumab was 11 months and the median follow up time after bevacizumab treatment was 8 months. The median number of cycles of bevacizumab was administered was 4, and the median dosage of bevacizumab was 7.5 mg/kg. The median time elapsed between cycles of bevacizumab was 2 weeks. Overall, pre and post treatment imaging revealed a median decrease in T1 contrast enhancement of 63 %, and a 59 % median decrease in T2/FLAIR signal abnormality. Treatment with bevacizumab resulted in a significant radiographic response for patients with radionecrosis. The median dosage of bevacizumab of 7.5 mg/kg for four cycles every 2 weeks should be considered as a treatment option in this patient population.
KeywordsBevacizumab Radiation necrosis Radiation Brain tumors
Conflict of interest
The authors’ report that Dr. Kelly Nicholas is a consultant for Genentech.
- 1.Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Grewal J, Prabhu S, Loghin M, Gilbert MR et al (2011) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79:1487–1495. doi: 10.1016/j.ijrobp.2009.12.061 PubMedCentralPubMedCrossRefGoogle Scholar
- 6.Nonoguchi N, Miyatake S, Fukumoto M, Furuse M, Hiramatsu R, Kawabata S, Kuroiwa T, Tsuji M, Fukumoto M, Ono K (2011) The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: pathological consideration of their potential roles. J Neurooncol 105:423–431. doi: 10.1007/s11060-011-0610-9 PubMedCrossRefGoogle Scholar
- 26.Perez-Espejo MA, Garcia-Fernandez R, Tobarra-Gonzalez BM, Palma-Copete JD, Gonzalez-Lopez A, De la Fuente-Munoz I, Salinas-Ramos J, Felipe-Murcia M, Martinez-Lage JF, Fernandez-Perez J et al (2009) Usefulness of hyperbaric oxygen in the treatment of radionecrosis and symptomatic brain edema after LINAC radiosurgery. Neurocirugia 20:449–453PubMedGoogle Scholar
- 27.Kang KB, Wang TT, Woon CT, Cheah ES, Moore XL, Zhu C, Wong MC (2007) Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. Int J Radiat Oncol Biol Phys 67:888–896. doi: 10.1016/j.ijrobp.2006.09.055 PubMedCrossRefGoogle Scholar
- 33.Merkenschlager A, Hirsch W, Syrbe S, Bernhard M, Wurm R (2011) Successful bevacizumab therapy for CNS radiation necrosis after stereotactic radiotherapy of an arteriovenous malformation. Neuropediatrics 42:P046Google Scholar